Neuland Laboratories reported Q4 FY26 total income of ₹788.7 crore, up 134.9% YoY and 76.1% QoQ.
EBITDA reached ₹319.4 crore with margin expansion of 2316 bps YoY to 40.5%, while PAT grew 666.3% YoY to ₹212.5 crore.
Management highlighted strong business visibility from commercial molecules and ongoing investments in peptide manufacturing and new R&D centre.
The company will host an earnings call on May 12, 2026, to discuss these results and future outlook.